Salidroside inhibits endothelial‑mesenchymal transition via the KLF4/eNOS signaling pathway

Huang,Yongpan; Han,Xiaodong; Tang,Jiayu; Long,Xian; Wang,Xiaoye

doi:10.3892/mmr.2021.12324

Salidroside inhibits endothelial‑mesenchymal transition via the KLF4/eNOS signaling pathway

Authors:
- Yongpan Huang
- Xiaodong Han
- Jiayu Tang
- Xian Long
- Xiaoye Wang
View Affiliations

Affiliations: Department of Clinic, Medicine School, Changsha Social Work College, Changsha, Hunan 410004, P.R. China, Department of Anesthesia, Medical College, Yan'an University, Yan'an, Shanxi 716000, P.R. China, Department of Neurology, Brain Hospital of Hunan Province, Changsha, Hunan 410007, P.R. China
Published online on: August 1, 2021 https://doi.org/10.3892/mmr.2021.12324
Article Number: 692
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Homocysteine (Hcy) was discovered to be an independent risk factor for the development of atherosclerosis (AS). Moreover, endothelial‑mesenchymal transition (EndMT) was found to be one of main mechanisms contributing to the pathogenesis of AS. Salidroside (SAL) has diverse pharmacological activities, including anti‑inflammatory, anti‑cancer, anti‑oxidative and anti‑fibrosis properties. However, whether SAL serves a beneficial role in Hcy‑induced EndMT remains unknown. The present study aimed to investigate whether SAL exerted its effects on Hcy‑induced EndMT via the Kruppel‑like factor 4 (KLF4)/endothelial nitric oxide (NO) synthase (eNOS) signaling pathway. HUVECs were pretreated with high and low doses (10 or 50 µmol/l) of SAL for 2 h, followed by 1 mmol/l Hcy for 48 h to induce EndMT. Western blotting was used to analyze the protein expression levels of the endothelial marker, VE‑cadherin, the mesenchymal cell marker, α‑smooth muscle actin (SMA), and the nuclear transcription factors, KLF4 and eNOS. Wound healing assays were used to determine the cell migratory ability, and the levels of NO in the cell culture supernatants were measured using a nitrate reductase assay. Cellular immunofluorescence was used to analyze the expression and localization of KLF4. Small interfering (si)RNA targeting KLF4 (siKLF4) was used to knock down KLF4 expression in HUVECs. The results of the present study revealed that treatment with SAL upregulated the expression levels of VE‑cadherin, downregulated the expression levels of α‑SMA, reduced cell migration and activated the eNOS/NO signaling axis, as well as downregulated KLF4 expression and translocation to the nucleus. Compared with the SAL + siKLF4 co‑administration group, no significant differences were observed in the expression levels of the phenotypic markers in the SAL or siKLF4 groups. In conclusion, the findings of the present study revealed that SAL may inhibit Hcy‑induced EndMT via regulation of the KLF4/eNOS signaling pathway.

View Figures

View References

1	Xu X, Friehs I, Hu TZ, Melnychenko I, Tampe B, Alnour F, Iascone M, Kalluri R, Zeisberg M, Del Nido PJ and Zeisberg EM: Endocardial fibroelastosis is caused by aberrant endothelial to mesenchymal transition. Circ Res. 116:857–866. 2015. View Article : Google Scholar : PubMed/NCBI
2	Bischoff J: Endothelial-to-mesenchymal transition. Circ Res. 124:1163–1165. 2019. View Article : Google Scholar : PubMed/NCBI
3	Qin W, Zhang L, Li Z, Xiao D, Zhang Y, Zhang H, Mokembo JN, Monayo SM, Jha NK, Kopylov P, et al: Endothelial to mesenchymal transition contributes to nicotine-induced atherosclerosis. Theranostics. 10:5276–5289. 2020. View Article : Google Scholar : PubMed/NCBI
4	Wadhera RK, Steen DL, Khan I, Giugliano RP and Foody JM: A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. J Clin Lipid. 10:472–489. 2016. View Article : Google Scholar : PubMed/NCBI
5	Guo Y, Li P, Bledsoe G, Yang ZR, Chao L and Chao J: Kallistatin inhibits TGF-β-induced endothelial-mesenchymal transition by differential regulation of microRNA-21 and eNOS expression. Exp Cell Res. 337:103–110. 2015. View Article : Google Scholar : PubMed/NCBI
6	Yoshida T, Yamashita M and Hayashi M: Kruppel-like factor 4 contributes to high phosphate-induced phenotypic switching of vascular smooth muscle cells into osteogenic cells. J Biol Chem. 287:25706–25714. 2012. View Article : Google Scholar : PubMed/NCBI
7	Sun Q, Gong L, Qi R, Qing W, Zou M, Ke Q, Zhang L, Tang X, Nie Q, Yang Y, et al: Oxidative stress-induced KLF4 activates inflammatory response through IL17RA and its downstream targets in retinal pigment epithelial cells. Free Rad Biol Med. 147:271–281. 2020. View Article : Google Scholar : PubMed/NCBI
8	Zhong Z, Han J, Zhang J, Xiao Q, Hu J and Chen L: Pharmacological activities, mechanisms of action, and safety of salidroside in the central nervous system. Drug Des Devel Ther. 12:1479–1489. 2018. View Article : Google Scholar : PubMed/NCBI
9	Zheng L, Su J, Zhang Z, Jiang L, Wei J, Xu X and Lv S: Salidroside regulates inflammatory pathway of alveolar macrophages by influencing the secretion of miRNA-146a exosomes by lung epithelial cells. Sci Rep. 10:207502020. View Article : Google Scholar : PubMed/NCBI
10	Lai W, Xie X, Zhang X, Wang Y, Chu K, Brown J, Chen L and Hong G: Inhibition of complement drives increase in early growth response proteins and neuroprotection mediated by salidroside after cerebral ischemia. Inflammation. 41:449–463. 2018. View Article : Google Scholar : PubMed/NCBI
11	Xing SS, Yang J, Li WJ, Li J, Chen L, Yang YT, Lei X, Li J, Wang K and Liu X: Salidroside decreases atherosclerosis plaque formation via inhibiting endothelial cell pyroptosis. Inflammation. 43:433–440. 2020. View Article : Google Scholar : PubMed/NCBI
12	Zhu L, Jia F, Wei J, Yu Y, Yu T, Wang Y, Sun J and Luo G: Salidroside protects against homocysteine-induced injury in human umbilical vein endothelial cells via the regulation of endoplasmic reticulum stress. Cardiovasc Ther. 35:33–39. 2017. View Article : Google Scholar : PubMed/NCBI
13	Zhang Yanyan, He Li, Huang Mei, Jiang Feng, Fu Lingyun and Li Jiachuan: Salidroside inhibits homocysteine induced oxidative stress in human umbilical vein endothelial cells. Journal of Southwest Minzu University (Natural Science Edition). 2020.46((04)): 349–353, (In Chinese).
14	Xing SS, Li J, Chen L, Yang YF, He PL, Li J and Yang J: Salidroside attenuates endothelial cellular senescence via decreasing the expression of inflammatory cytokines and increasing the expression of SIRT3. Mech Ageing Dev. 175:1–6. 2018. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Song S, Zhang R, Cao W, Fang G, Yu Y, Wan Y, Wang C, Li Y and Wang Q: Foxm1 is a critical driver of TGF-β-induced EndMT in endothelial cells through Smad2/3 and binds to the snail promoter. J Cell Physiol. 234:9052–9064. 2019. View Article : Google Scholar : PubMed/NCBI
17	van Putten S, Shafieyan Y and Hinz B: Mechanical control of cardiac myofibroblasts. J Mol Cell Cardiol. 93:133–142. 2016. View Article : Google Scholar : PubMed/NCBI
18	Gimbrone MA Jr and García-Cardeña G: Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. 19:620–636. 2016. View Article : Google Scholar : PubMed/NCBI
19	Song CL, Liu B, Shi YF, Liu N, Yan YY, Zhang JC, Xue X, Wang JP, Zhao Z, Liu JG, et al: MicroRNA-130a alleviates human coronary artery endothelial cell injury and inflammatory responses by targeting PTEN via activating PI3K/Akt/eNOS signaling pathway. Oncotarget. 7:71922–71936. 2016. View Article : Google Scholar : PubMed/NCBI
20	Wang XJ, Tian DC, Wang FW, Zhang MH, Fan CD, Chen W, Wang MH, Fu XY and Ma JK: Astaxanthin inhibits homocysteine-induced endothelial cell dysfunction via the regulation of the reactive oxygen species-dependent VEGF-VEGFR2-FAK signaling pathway. Mol Med Rep. 19:4753–4760. 2019.PubMed/NCBI
21	Rajendran S, Shen X, Glawe J, Gopi K, Kolluru GK and Kevil CG: Nitric oxide and hydrogen sulfide regulation of ischemic vascular growth and remodeling. Compr Physiol. 12:1213–1247. 2019. View Article : Google Scholar : PubMed/NCBI
22	Tan X, Feng L, Huang X, Yang Y, Yang C and Gao Y: Histone deacetylase inhibitors promote eNOS expression in vascular smooth muscle cells and suppress hypoxia-induced cell growth. J Cell Mol Med. 21:2022–2035. 2017. View Article : Google Scholar : PubMed/NCBI
23	Liu S, Sun Z, Chu P, Li H, Ahsan A, Zhou Z, Zhang Z, Sun B, Wu J, Xi Y, et al: EGCG protects against homocysteine-induced human umbilical vein endothelial cells apoptosis by modulating mitochondrial-dependent apoptotic signaling and PI3K/Akt/eNOS signaling pathways. Apoptosis. 22:672–680. 2017. View Article : Google Scholar : PubMed/NCBI
24	Arab HH, Salama SA and Maghrabi IA: Camel milk attenuates methotrexate-induced kidney injury via activation of PI3K/Akt/eNOS signaling and intervention with oxidative aberrations. Food Funct. 9:2661–2672. 2018. View Article : Google Scholar : PubMed/NCBI
25	Li J, Xiang X, Xu H and Shi Y: Cilostazol promotes angiogenesis and increases cell proliferation after myocardial ischemia-reperfusion injury through a cAMP-dependent mechanism. Cardiovasc Eng Technol. 10:638–647. 2019. View Article : Google Scholar : PubMed/NCBI
26	Zhang Y, Li C, Huang Y, Zhao S, Xu Y, Chen Y, Jiang F, Tao L and Shen X: EOFAZ inhibits endothelial-to-mesenchymal transition through downregulation of KLF4. Int J Mol Med. 46:300–310. 2020.PubMed/NCBI